A meta‐analysis of 9 randomized trials of P2Y12 inhibitor monotherapy or aspirin for secondary prevention involving 42 108 patients found a borderline risk reduction conferred by P2Y12 inhibitor for myocardial infarction (odds ratio, 0.81; 95% CI, 0.66–0.99) but no evidence of a between‐group difference in the risks of bleeding or all‐cause mortality.6 Here, P2RY12 is linked to myocardial infarction.